Extracellular Domain Mutation of ErbB2 Status in Japanese Lung Cancer Patients
Journal Title: Journal of Oncobiomarkers - Year 2013, Vol 1, Issue 2
Abstract
Purpose: The erbB pathway involves a family of tyrosine kinases and has contributed to resistance or sensitivity for chemotherapy in many tumor types. Somatic mutations of the erbB family receptor gene at kinase domain were found in lung cancer patients. However, the incidence of extracellular domain mutation of erbB2 in Japanese patients has been rarely described. We report on the incidence of these mutations and clinical factors associated with these mutations. Material and Methods: We have investigated extracellular domain mutations of erbB2 status in non-small cell lung cancer (NSCLC) patients by reverse transcript polymerase chain reaction (RT-PCR) and direct sequencing. The study included 210 surgically removed EGFR or ALK gene wild type lung cancer cases from Nagoya City University Hospital. Results: One G309E erbB2 mutation case was found from squamous cell carcinoma. Within adenocarcinoma, no erbB2 mutation was found in extracellular domain. We have previously detected six erbB2 mutations at kinase domain all in adenocarcinomas. Among the 7 erbB2 gene mutation cases, one case with kinase domain mutation was Hercep test positive. Conclusion: The extracellular domain mutation of erbB2 was rare in Japanese population. Although this mutation is rare, its identification could result in more precise treatment of patients. Keywords: Extracellular domain; squamous cell carcinoma; Lung cancer; Mutations; erbB2; G309E
Authors and Affiliations
Hidefumi Sasaki
Keywords
Related Articles
- EP ID EP206249
- DOI 10.13188/2325-2340.1000006
- Views 96
- Downloads 0
11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis
Colorectal cancer (CRC) is a leading cause of cancer death, yet primary prevention remains the best approach to reducing overall morbidity and mortality. There is a clear molecular link between cyclooxygenase-2 (COX-2)-d...
IRF4 as an Oncogenic Biomarker for Hematological Malignancies
The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is crucial for lymphocyte development. Importantly, IRF4 has potent oncogenic and transforming properties, and its intimate interac...
Redefining the HER2 Oncobiomarker: A Relevant Case Report
In multiple studies anti HER2 therapy combined with chemotherapy demonstrated a marked improvement in disease free survival as adjuvant therapy and as treatment for metastatic breast cancer compared to chemotherapy alone...
Suppression of Matrix Metalloproteinases -2 and -9 in Various Human Cancer Cell Lines by a Nutrient Mixture
The matrix metalloproteinases (MMPs) are a family of zinc containing endopeptidases that degrade various components of the extra cellular matrix. Among the many types of MMPs that have been identified, MMP-2 (gelatinase...
Involvement of Sphingosine Kinases/Sphingosine-1-Phosphate (S1P)/S1P Receptors in Breast Cancer Subtypes
There is emerging evidence suggesting sphingolipids as critical regulators of cancer development and progression. Sphingolipids are potent bioactive lipids involved in fundamental biological processes including cell prol...